← Back to headlines
Teva and Sanofi Report Positive Phase 2b Results for Ulcerative Colitis and Crohn's Disease Drug
Teva and Sanofi announced durable phase 2b efficacy results for their drug duvakitug, intended for the treatment of ulcerative colitis and Crohn's disease.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
